Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 65

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 65
---
 one warrant for aggregate gross proceeds of approximately $2.25 million.

In
June 2022, we entered into an At The Market Offering Agreement (the “ATM Agreement”) which was amended on September 1, 2022
with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which we may offer and sell, from time to
time through Wainwright, shares of our common stock for aggregate gross proceeds of up to $3.7 million. The issuance and sale of common
stock by us under the ATM Agreement is currently being made pursuant to our effective “shelf” registration statement on Form
S-3 filed with the SEC on August 13, 2025 and declared effective on August 20, 2025. In 2024, we sold 5,428 shares of our common stock
for aggregate gross proceeds of approximately $0.4 million. On September 2, 2025, we filed a prospectus supplement to increase the amount
of shares registered under the prospectus for the ATM Agreement to $2.34 million. In September  2025, we sold 520,000 shares of
our common stock for aggregate gross proceeds of approximately $2.34 million.

6

We
believe that our cash and cash equivalents of approximately $5.8 million that we had as of September 30, 2025 will enable us to fund
our operating expenses and capital expenditure requirements into the first quarter of 2026 based on our current operating plan. We will
need to increase our capital resources through equity or debt financings, and we may need to do so sooner than we expect. We may also
seek to finance our cash needs through collaborations, strategic alliances, or license agreements with third parties. If sources of financing
are available, they may result in substantial dilution to our stockholders. We cannot provide any assurance that new financing will be
available to us on commercially acceptable terms or in the amounts required, if at all. If we are unable to consummate a financing or
other transaction, we may need to delay, reduce, or eliminate our research and development programs, which could adversely affect our
business prospects, or cease operations. These conditions raise substantial doubt regarding our ability to continue as a going concern
within one year after the date of the filing of this Quarterly Report. For additional information, see Note 1 to our unaudited condensed
consolidated financial statements included